Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice

Drug and Alcohol Dependence
Travis W GrimAron H Lichtman

Abstract

Synthetic cannabinoids have emerged as a significant public health concern. To increase the knowledge of how these molecules interact on brain reward processes, we investigated the effects of CP55,940, a high efficacy synthetic CB1 receptor agonist, in a frequency-rate intracranial self-stimulation (ICSS) procedure. The impact of acute and repeated administration (seven days) of CP55,940 on operant responding for electrical brain stimulation of the medial forebrain bundle was investigated in C57BL/6J mice. CP55,940 attenuated ICSS in a dose-related fashion (ED50 (95% C.L.)=0.15 (0.12-0.18)mg/kg). This effect was blocked by the CB1 receptor antagonist rimonabant. Tolerance developed quickly, though not completely, to the rate-decreasing effects of CP55,940 (0.3mg/kg). Abrupt discontinuation of drug did not alter baseline responding for up to seven days. Moreover, rimonabant (10mg/kg) challenge did not alter ICSS responding in mice treated repeatedly with CP55,940. The finding that CP55,940 reduced ICSS in mice with no evidence of facilitation at any dose is consistent with synthetic cannabinoid effects on ICSS in rats. CP55,940-induced ICSS depression was mediated through a CB1 receptor mechanism. Additionally, tolerance and dep...Continue Reading

References

Aug 1, 1992·Journal of Pain and Symptom Management·T L Yaksh
Oct 1, 1990·Trends in Neurosciences·A C HowlettM Herkenham
Nov 1, 1991·Pharmacology, Biochemistry, and Behavior·R MechoulamJ Zahalka
Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M HerkenhamK C Rice
Jan 1, 1988·Psychopharmacology·E L GardnerD Morrison
May 1, 1995·Anesthesiology·A Duttaroy, B C Yoburn
May 13, 1999·Proceedings of the National Academy of Sciences of the United States of America·A ZimmerT I Bonner
Oct 12, 1999·British Journal of Pharmacology·G GriffinM E Abood
May 14, 2003·Behavioural Brain Research·Styliani VlachouGeorge Panagis
May 7, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Joseph F CheerR Mark Wightman
Apr 12, 2005·Psychopharmacology·Styliani VlachouGeorge Panagis
Jun 30, 2005·Psychopharmacology·Benoît ForgetMarie-Hélène Thiébot
Mar 30, 2006·International Journal of Obesity : Journal of the International Association for the Study of Obesity·R G Pertwee
Sep 6, 2006·Psychopharmacology·Styliani VlachouGeorge Panagis
Nov 17, 2007·Nature Protocols·William A Carlezon, Elena H Chartoff
Jan 27, 2010·Psychopharmacology·S Stevens NegusKenner C Rice
Jul 14, 2010·Bioorganic & Medicinal Chemistry·John W HuffmanBilly R Martin
Jul 28, 2012·Journal of Forensic Sciences·Barry K LoganFrancis X Diamond
Aug 16, 2012·The Journal of Pharmacology and Experimental Therapeutics·Andrew J Kwilasz, S Stevens Negus
Jul 3, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Francisco NavarreteJorge Manzanares
Jul 9, 2013·The International Journal of Neuropsychopharmacology·Vicky KatsidoniGeorge Panagis
Jul 25, 2013·Human Psychopharmacology·Duccio PapantiTommaso Bonavigo
Oct 22, 2013·Drug and Alcohol Dependence·Jane Carlisle Maxwell
Apr 2, 2014·Toxicology and Applied Pharmacology·Verena J KollerSiegfried Knasmüller
Jun 29, 2014·Pharmacological Reviews·S Stevens Negus, Laurence L Miller

❮ Previous
Next ❯

Citations

Jul 12, 2017·Behavioural Pharmacology·Nicholas PintoriMaddalena Mereu
Dec 23, 2020·Journal of Neuroscience Research·Aida Mohammadkhani, Stephanie L Borgland
Mar 19, 2019·Neuropharmacology·Megan J Moerke, S Stevens Negus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.